People · Operator
Named in public records as an officer, director or promoter · active 2011–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Atox Bio Inc. | — | Biotechnology | Series B | $35.1M | $1.3B | 2011 |
| Nasus Pharma Ltd | — | Biotechnology | Series B | $15.0M | $53.5M | 2026 |
Dan Teleman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dan Teleman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Erez Chimovits | 1 | 7 |
| Terry Gould | 1 | 6 |
| Casper Breum | 1 | 5 |
| Daniel Burgess | 1 | 4 |
| Sharon Shacham | 1 | 4 |
| Dalia Megiddo | 1 | 3 |
| Ronnie Hershman | 1 | 2 |
| Arnon Aharon | 1 | 2 |
| Jonathan Tobin | 1 | 2 |
| David Silberman | 1 | 2 |
| Matthew Foy | 1 | 2 |
| Udi Gilboa | 1 | 2 |
| Isaac Israel | 1 | 2 |
| DANE ROSS | 1 | 1 |
| Newton Becker | 1 | 1 |
| Uri Danon | 1 | 1 |
| Raymond Kaempfer | 1 | 1 |
| Bob Trachtenberg | 1 | 1 |
| Eyal Rubin | 1 | 1 |
| ESTHER HAYUN | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.